ALDH+/CD44+ cells in breast cancer are associated with worse prognosis and poor clinical outcome

Qiu, Yan; Pu, Tianjie; Guo, Ping; Wei, Bing; Zhang, Zhang; Zhang, Hongying; Zhong, Xiaorong; Zheng, Hong; Chen, Lina; Bu, Hong; Feng, Yan

doi:10.1016/j.yexmp.2015.11.032

Cited by 22 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the CD44 high /CD24 low /ALDH high subpopulation is able to generate tumors with as few as 20 cells [ 101 ] . This is consistent with the clinical data where ALDH high / CD44 high is frequently found in patients with breast cancer and associated with increased tumor growth, disease progression, metastasis, and worsened prognosis despite radiotherapy, endocrine therapy, or chemotherapy [ 101 , 103 - 104 ] . From the current literature, it seems that the CD44 high /CD24 low /ALDH high may be used for the detection of hybrid E/M CSCs.…”

Section: Investigation Of Hybrid E/m With Improved Methodologiessupporting

confidence: 92%

Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression

2018

View full text Add to dashboard Cite

Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are essential for embryonic development and also important in cancer progression. In a conventional model, epithelial-like cancer cells transit to mesenchymal-like tumor cells with great motility via EMT transcription factors; these mesenchymal-like cells migrate through the circulation system, relocate to a suitable site and then convert back to an epithelial-like phenotype to regenerate the tumor. However, recent findings challenge this conventional model and support the existence of a stable hybrid epithelial/mesenchymal (E/M) tumor population. Hybrid E/M tumor cells exhibit both epithelial and mesenchymal properties, possess great metastatic and tumorigenic capacity and are associated with poorer patient prognosis. The hybrid E/M model and associated regulatory networks represent a conceptual change regarding tumor metastasis and organ colonization. It may lead to the development of novel treatment strategies to ultimately stop cancer progression and improve disease-free survival.

show abstract

Section: Investigation Of Hybrid E/m With Improved Methodologiessupporting

confidence: 92%

Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression

2018

View full text Add to dashboard Cite

show abstract

“…An increasing number of studies have shown that an enlarged cancer stem cell population is highly associated with tumor metastatic ability and cancer stem cells can be extended to drive cancer progression. Although there is a degree of consensus on the use of certain CSC markers, some controversy persists about the need to identify further markers [7]. In the current study, we found a strong significant correlation between CD44 expression and histological grade, lymph node metastasis, and stage of the tumor (P < 0.0001).…”

Section: Discussionsupporting

confidence: 42%

“…CSCs are capable of high proliferation rate, self-renewal, and multidirectional differentiation associated with an important role in tumorigenesis, growth, invasion, metastasis, and recurrence [4]. Minimizing the rate of breast cancer recurrence and improving the rate of the cure in clinical practice has been based on the intense exploration of CSCs [6,7].…”

Section: Introductionmentioning

confidence: 99%

TP53 Mutation in Saudi Breast Cancer Patients: Correlations with Cancer Stem Cell Markers Expression and Clinicopathological Variables

Nassir¹,

Elmoneim²,

Esheba³

et al. 2020

SJPM

View full text Add to dashboard Cite

Background: Breast cancer is one of the most common cancers with a high mortality rate worldwide including Saudi Arabia. It is characterized by the presence of both intra-and inter-tumor heterogeneity. It describes the origin of this heterogeneity to the cancer stem cells (CSC). Breast cancer stem cells are characterized by the expression of the surface markers CD44 and lack or very low expression of CD24. Objectives: To assess cancer stem cell markers (CD44 andCD24) in 126 breast cancer cases by immunohistochemistry and study their association with a different type of TP53 gene mutations by applying next-generation sequencing (NGS). In addition to analyze the association between these markers and the clinicopathological characteristics. Results: CD44 expression was significantly associated with lymph node metastasis, tumor grade, stage (each P<0.0001), and ER expression (P = 0.016). CD24 expression was found to be associated with lymph node metastasis and ER only. For the molecular analysis, the number of mutations per case was significantly associated with the advanced stage of breast cancer (p = 0.004). Also, missense mutation was highly associated with CD44 and CD24 (p=0.04, p=0.005), respectively. Stop-gained mutation and Frameshift mutation both were associated with CD44 only (p=0.01, p=0.05), respectively. Finally, the synonymous mutation was only associated with the stage of cancer (p=0.01). Conclusion, we believe that the combination of CD44, CD24, TP53 and TP53 gene mutations can be prognostic factors for breast cancer patients and the information obtained may contribute to the development of a treatment.

show abstract

“…Some cases have been identified in ovarian cancer[91,92], invasive ductal breast carcinoma tumors[93], and lung cancer[94]. The combination ALDH + /CD44 + has been evaluated in various tumors such as breast cancer[95] and lung cancer[96].…”

Section: Csc Characteristics With Clinical Relevancementioning

confidence: 99%

Cancer stem cell impact on clinical oncology

Toledo-Guzmán

Bigoni-Ordóñez

Hernández

et al. 2018

WJSC

View full text Add to dashboard Cite

Cancer is a widespread worldwide chronic disease. In most cases, the high mortality rate from cancer correlates with a lack of clear symptoms, which results in late diagnosis for patients, and consequently, advanced tumor disease with poor probabilities for cure, since many patients will show chemo- and radio-resistance. Several mechanisms have been studied to explain chemo- and radio-resistance to anti-tumor therapies, including cell signaling pathways, anti-apoptotic mechanisms, stemness, metabolism, and cellular phenotypes. Interestingly, the presence of cancer stem cells (CSCs), which are a subset of cells within the tumors, has been related to therapy resistance. In this review, we focus on evaluating the presence of CSCs in different tumors such as breast cancer, gastric cancer, lung cancer, and hematological neoplasias, highlighting studies where CSCs were identified in patient samples. It is evident that there has been a great drive to identify the cell surface phenotypes of CSCs so that they can be used as a tool for anti-tumor therapy treatment design. We also review the potential effect of nanoparticles, drugs, natural compounds, aldehyde dehydrogenase inhibitors, cell signaling inhibitors, and antibodies to treat CSCs from specific tumors. Taken together, we present an overview of the role of CSCs in tumorigenesis and how research is advancing to target these highly tumorigenic cells to improve oncology patient outcomes.

show abstract

ALDH+/CD44+ cells in breast cancer are associated with worse prognosis and poor clinical outcome

Cited by 22 publications

References 32 publications

Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression

Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression

TP53 Mutation in Saudi Breast Cancer Patients: Correlations with Cancer Stem Cell Markers Expression and Clinicopathological Variables

Cancer stem cell impact on clinical oncology

Contact Info

Product

Resources

About